Bell Potter downgrade 23 November 2015, page-148

Carefully read some of the posts from other posters, they also understand bios.

You refuse to extrapolate using proper criteria for LT investing for biotechs. You get data like the aGVHD remimbursement and REFUSE to see any positives. You cannot give any weight at all to the robustness of the science. NONE.

You act as if the IPO listing failed and no funds were gained. All you can talk about is the SP. You can't see beyond it.

There is no traction with you on any of the issues raised, you just keep on like a stuck record, wheeling out your broker talk, recycled from years of spin, to make people fearful or have FOMO, in this case the former.

It's hard work talking to someone with learning difficulties about biotechs. People who got scared out of their shares aren't going to thank you with your 'value investing' model, that's for sure.